Establishment and genetic characterization of cell lines derived from proliferating nasal polyps and sinonasal inverted papillomas

Thawaree Nukpook¹,², Tipaya Ekalaksananan¹,², Tohru Kiyono³, Pornthep Kasemsiri⁴, Watchareporn Teeramatwanich⁵,⁶, Patravoot Vatanasapt⁵,⁶, Surachat Chaiwiriyyakul⁵, Patravoot Vatanasapt²,⁶, Watchareporn Teeramatwanich⁵,⁶, Piti Ungarreevittaya⁴, Jureeporn Kampan⁵, Kanha Muisuk⁵ & Chamsai Pientong¹,²

To better understand the pathogenesis of nasal polyps (NPs) and sinonasal inverted papillomas (SIPs), we aimed to establish cell lines from fresh tissues of NPs and SIPs and characterize them. Primary cell cultures were obtained from two NP tissues (NP2 and NP3) and one SIP tissue (IP4). All the cells were polygonal in shape, expressed cytokeratin 14, and had normal diploid chromosome status. HPV58 DNA was detected in NP3. To obtain immortal primary cells, NP2 and IP4 cells were transduced with a combination of mutant CDK4, cyclinD1 and TERT. These cells were thereafter named NP2/K4DT and IP4/K4DT, respectively. HPV58-positive NP3 cells were transduced with TERT alone, the resulting cells named NP3/T. Phenotypic and genotypic identity of original tissues and derived cells was investigated. All the cell cultures with transgenes were confirmed to be derived from their parental cells and primary tumor tissues by analysis of short tandem repeats (STR) and maintained in vitro growth, genetic profiles and gene expression characteristics of the primary cells. These virtually immortalized cells, as well as the primary cells, have potential as in vitro models for studying the pathogenesis of NPs and SIPs and for preclinical study to develop new therapeutic agents.

Nasal polyps (NPs) are common, but benign, hyperplastic growths of the nasal mucosa¹. Patients with NPs might be asymptomatic or might have various nasal problems such as nasal obstruction, rhinorrhea, and nasal congestion². NPs frequently recur and are mostly associated with chronic rhinosinusitis³. Even though they are common, their etiology and pathogenesis are poorly understood¹. Several causes of NPs have been proposed such as inflammation, neoplastic origin, bacterial infection, and fungal infection, but the precise mechanisms are still under investigation⁴. There is no effective treatment for NPs: treatment strategies only focus on the reduction of NP symptoms by using medical or surgical approaches according to the inflammatory or neoplastic origin of the NPs⁴. Despite attempts to define a core set of biomarkers that are related to NP pathogenesis to improve treatment outcomes, only limited progress has been made⁹–¹². More research is needed to elucidate underlying molecular mechanisms of NP pathogenesis and to develop new therapeutics.

Sinonasal inverted papillomas (SIPs) are benign tumors of the nasal cavity and paranasal sinuses¹³,¹⁴. SIPs are characterized by the inward growth of epithelial cells into the underlying supportive tissue¹⁵. It is the second-most common benign tumor of the sinonasal tract, representing approximately 0.5–4% of all primary nasal tumors, and is more frequently found in males than in females in the fifth and sixth decades of life¹⁴. The etiology and pathogenesis of SIPs remain unclear¹⁷. Moreover, SIPs frequently recur following treatment and can cause local destruction¹⁸. A relationship between SIPs and sinonasal squamous-cell carcinoma (SNSCC) has not been definitively established. Therefore, the development of new therapeutic agents is urgently needed for SIP patients to improve their outcomes.

¹Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. ²HPV & EBV and Carcinogenesis Research Group, Khon Kaen University, Khon Kaen, Thailand. ³Project for Prevention of HPV-Related Cancer, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. ⁴Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. ⁵Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. ⁶Department of Forensic Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. ªemail: tkiyono@east.ncc.go.jp; chapie@kku.ac.th
been reported\cite{19,20}. The SIP treatment of choice is surgical removal of the tumor mass: its success depends on complete resection of the entire tumor. Preoperative medical treatment is used to reduce existing inflammation and intraoperative bleeding to improve conditions for surgery. In some cases, such as SIP-associated carcinoma if surgery is impossible, radiation therapy might be considered\cite{21}. A review of surgical outcomes of 36 SIP cases spanning 17 years reported a recurrence rate of 13.3% and 16.6% of cases who underwent endoscopic and combined/open approaches, respectively\cite{22}. Despite improved treatment strategies, the recurrence rate of SIP is still high, and new, alternative, treatment strategies are required. Due to the rarity of this disease, there is limited information on its characteristics and treatment outcomes. An in vitro model might be a good system in which to study SIP etiology, biology and pathogenesis.

More studies on NPs and SIPs are required to understand their pathogenesis. Cell lines have been widely used as in vitro models for research into tumor biology\cite{23}. They are useful for the study of the genetic and epigenetic basis of many diseases and excellent models for understanding a range of biological mechanisms including tumorigenesis. Examples include the investigation of deregulated genes, proteins and signaling pathways during disease initiation and progression. Moreover, cell lines can be used for the development of new therapeutic strategies and preclinical testing. In this study, we aimed to establish new sinonasal cell lines from NP and SIP tissues to characterize their chromosomes and genetic alterations. Three new primary sinonasal cells and their derivatives were established from two NPs and one SIP tissue. They should be useful in vitro tools for studying the pathogenesis of NPs and SIPs and for preclinical testing of new therapeutic agents.

**Results**

**Characteristics of primary cells.** Primary sinonasal cells were obtained from fresh tissues of two NP patients named NP2 and NP3, and from one SIP patient named IP4. All the cells grew as monolayers in cell-culture flasks and were polygonal in shape, as shown in Fig. 1. The population-doubling time ranged between 55 and 63 h: IP cells grew faster than NP cells (Fig. 2). NP2, NP3, and IP4 cells could be subcultured until passages 13, 12, and 13, respectively.

HPV DNA was detected in NP3 cells, and reverse line-blot hybridization (RLBH) revealed the presence of HPV58 DNA in this case. NP2 and IP4 showed no evidence of HPV infection.

**Figure 1.** Photomicrograph of a representative H&E stained paraffin section of the original primary tumor (left), and the polygonal morphology of established primary cells (middle) and primary immortal cells (right). The primary cells, NP2, IP4, and NP3 were transduced with a combination of CDK4R24C, cyclin D1, and TERT or TERT alone, respectively, to obtain primary immortal cells. All established cells were cultivated in FYAD-medium in cell-culture flasks and incubated in 5% CO2 at 37 °C. At the 70–90% confluence, all established cells showed a similar morphological character to their primary tumor cells. Images were taken under the microscope with 200 x magnification (scale bars: 50 µm).
Immortalization and primary immortal cell characteristics. For the immortalization of normal human epithelial cells, both inactivation of the p16INK4A/pRB pathway and telomerase activation are required. Therefore, to obtain primary immortal cells, NP2 and IP4 cells were transduced with cyclin D1 and mutant CDK4 (CDK4R24C: a p16INK4A-resistant form of CDK4), cyclin D1, and TERT were examined in triplicate by western blotting. Cell morphology of NP2/K4DT and IP4/K4DT, and NP3/T was similar to that of their parental cells. The doubling times of all transduced cells were similar, but a little bit shortened compared to their parental cells (Fig. 2). At the time of writing, the current passage numbers for NP2/K4DT, NP3/T, and IP4/K4DT were 24, 23, and 30, respectively. We consider it likely that they were virtually immortalized though they have not reached 100 population doublings.

Short tandem repeat (STR) analysis. The STR analysis of the established primary and primary immortal cells was analyzed and compared to STR profiles of primary tumor tissues. According to the personal information protection law guidelines, not more than nine profiles of STR loci from each sample can be shown (Table 1): data from the remaining 15 loci are not shown. The established primary and primary immortal cells

Figure 2. Growth curves and population doubling time (DT) of NP2, NP3, and IP4 cells and their derivatives. Viable cells of the triplicate wells were counted every 24 h for 5 days as described in the Methods, and the mean and the SD were plotted (left panel). Population doubling time was calculated during the exponential growth phase as described in Methods (right). Note that IP4 and IP4/K4DT cells derived from an inverted papilloma showed a faster proliferation rate than NP2, NP2K4DT, NP3, and NP3/T cells derived from nasal polyp cells ($p = 0.0227$). DT: population doubling time.

Figure 3. Transgene expression in IP4/K4DT and NP2/K4DT cells. (A) Expression levels of CDK4 and cyclin D1, as well as vinculin as a loading control in IP4 and NP2 cells and those transduced with CDK4R24C, cyclin D1, and TERT were examined in triplicate by western blotting. (B) Band intensities of CDK4 and cyclin D1 (normalized against those of vinculin) were quantified and indicated as bar graphs. Asterisks indicate statistically significant differences (*$p < 0.05$; **$p < 0.01$), and “ns” indicates not significant.
share similar markers and match with the STR profiles of the primary tissues obtained from the patients. These results supported their identity and confirmed the same origin of the cells.

**Chromosome analysis.** The chromosomal karyotypes of all established cells were analyzed. Results demonstrated that the NP2, NP2/K4DT, NP3, NP3/T, IP4, and IP4/K4DT cells had human male karyotypes. All primary cell cultures (NP2, NP3, and IP4) had normal diploid chromosomes and did not show gains or losses of regions in chromosomes. Some chromosomal abnormalities were observed in some populations of primary immortal cells. In NP2/K4DT cells, there was a partial deletion of chromosome number 6 in 58% (29/50) of the cell populations. Chromosomal addition was found in some populations of NP3/T and IP4/K4DT. In NP2/K4DT cells, there was a partial deletion of chromosome number 6 in 58% (29/50) of the cell populations exhibited trisomy chromosome number 4, whereas a portion was added to chromosome number 8 in 52% (26/50) of IP4/K4DT cell populations as shown in Fig. 4.

**Genetic mutations analysis.** Various genetic alterations have been found and associated with tumorigenesis. Mutation of TP53, EGFR (ERBB1), KRAS, and PIK3CA are frequently observed in NP and SIP. Therefore, mutations of these genes at known mutation hotspot sites were investigated by sequencing. No mutations were found in NP3 (exons 5–9), KRAS (exon 2), and PIK3CA (exons 9 and 20) in any cells. In EGFR (exons 19 and 20), only IP4 and IP4/K4DT had an insertion mutation of 12 nucleotides (GTGACAACCACCC) in exon 20 leading to an insertion of four amino acids between amino acid residues N772 and H773 (Fig. 5). This mutation in IP4 was novel and named P772_H773insPYNP (Table 2). This mutation results in ligand-independent activation of EGFR as shown in Fig. 6, supplementary.

**Expression of EGFR, p53, KRAS, PIK3CA and cytokeratin 14.** To confirm the origin of the established primary cells, the expression of a squamous epithelium marker, cytokeratin 14 was investigated by western blot analysis. All established primary cells expressed cytokeratin 14, confirming their origin as keratinocytes as shown in Fig. 7A, supplementary. To investigate the gene-expression levels of EGFR, p53, KRAS, and PIK3CA in established cells and primary tissues, RT-qPCR was performed using specific primers. In tissue samples, the expression of PIK3CA was similar in all primary tissues. Higher levels of p53 were observed in IP tissue than NP tissues. Increased expression of KRAS was observed in IP4 tissue compared to others. Higher levels of EGFR were detected in HPV58-positive NP3 tissue and IP4 tissue compared to NP2 and normal nasal tissue as shown in Fig. 7B. In established cell cultures, a similar trend of gene expression level was observed as shown in Fig. 7C. For EGFR, PIK3CA and KRAS, gene expression levels were similar between primary and primary immortal cells in each case. There was increased expression of p53 in all primary immortal cells compared to their parental primary cells (Fig. 7C).

**Discussion**

In the present study, we describe the establishment of cell cultures from two NP and one SIP derived from samples with different clinical characteristics (Table 3). All cells were grown in monolayers. IP cells grew faster than NP cells (Fig. 2). Our result corresponded with studies of Mumbuc S et al. and Guichard C et al. who demonstrated that the epithelial cell proliferation rate of SIP was greater than that of NP and that expression levels of cell cycle-related proteins, PCAN, Ki-67, and p53 were increased in SIP tissues to a greater degree than in NP tissues. Upregulation of the proliferation marker, PCNA, is associated with an increase of p53 in NP relative to normal mucosa. In agreement with a previous report, our gene expression results showed higher p53 expression levels in SIP cells than NP cells (Fig. 7), though NP3 was HPV58-positive, implying expression levels of HPV58 E6 were not high enough to target p53 for degradation and to activate telomerase. The epithelial origin of all primary cell cultures was demonstrated by investigation of cytokeratin 14 expression (Fig. 7). HPV infection has been linked to some head and neck cancers and is frequently detected in tumors with intact TP53. HPV infection has been observed in up to 40% of NP and about 37.8% of SIP cases. HPV, therefore, seems to be associated with the development of NP and SIP, but its role in this development remains undetermined. Two established cells, NP3 and NP3/T, were positive for HPV58, whereas no HPV-DNA was detected in the other NP and IP cells (Table 2).

| Loci     | Tissue | Primary cells | Immortal cells | Tissue | Primary cells | Immortal cells | Tissue | Primary cells | Immortal cells |
|----------|--------|---------------|----------------|--------|---------------|----------------|--------|---------------|----------------|
| D3S1358  | 16, 16 | 16, 16        | 16, 16         | 16, 16 | 16, 16        | 16, 16         | 16, 16 | 16, 16        | 16, 16         |
| vWA      | 14, 17 | 14, 17        | 14, 17         | 14, 17 | 14, 17        | 14, 17         | 14, 17 | 14, 17        | 14, 17         |
| D16S539  | 10, 11 | 10, 11        | 10, 11         | 10, 11 | 11, 12        | 11, 12         | 11, 12 | 12, 14        | 12, 14         |
| CSF1PO   | 10, 10 | 10, 10        | 10, 10         | 11, 11 | 11, 11        | 11, 11         | 11, 11 | 11, 11        | 11, 11         |
| D6S1043  | 12, 17 | 12, 17        | 12, 17         | 12, 13 | 12, 13        | 12, 13         | 13, 13 | 13, 13        | 13, 13         |
| D8S1179  | 10, 13 | 10, 13        | 10, 13         | 14, 15 | 14, 15        | 14, 15         | 15, 15 | 15, 15        | 15, 15         |
| D21S11   | 30, 31,2 | 30, 31,2       | 32, 32,2       | 32, 32,2 | 30, 31, 30, 31 | 30, 31, 30, 31 | 30, 31, 30, 31 | 30, 31, 30, 31 | 30, 31, 30, 31 |
| D18S51   | 15, 15 | 15, 15        | 15, 15         | 12, 15 | 12, 15        | 12, 15         | 19, 21 | 19, 21        | 19, 21         |
| AMEL     | XY     | XY            | XY             | XY     | XY            | XY             | XY     | XY            | XY             |

Table 1. STR profiles of primary and primary immortal cells compared to primary tissues.
Figure 4. Karyotype variation of primary immortal cells compared to their primary cells. Karyotypes of NP2, NP2/K4DT, NP3, NP3/T, IP4, and IP4/K4DT were analyzed as described in Methods. The normal diploid chromosomes of primary cells (A,C,E) and representative images of abnormal karyotypes for NP2/K4DT (B), NP3/T (D), and IP4/K4DT (F) were presented. The results are summarized in the bottom table.

| Cells     | Total cell count (%) | Chromosome status  |
|-----------|----------------------|--------------------|
| NP2       | 50/50 (100%)         | 46,XY              |
| NP2/K4DT  | 21/50 (42%)          | 46,XY,del(6)(q21qter) |
| NP3       | 50/50 (100%)         | 46,XY              |
| NP3/T     | 5/50 (10%)           | 46,XY              |
| IP4       | 50/50 (100%)         | 46,XY,add(8)(q24)  |
| IP4/K4DT  | 24/50 (48%)          | 46,XY,add(8)(q24)  |
Figure 5. EGFR exon 20 insertion mutation in IP4 tissue and its derivatives. Mutation of EGFR exon 20 was analyzed by direct sequencing as described in Methods. (A) Schematic of wildtype- (Top) and IP4-derived EGFR exon 20 nucleotide and the corresponding amino acid sequences (Bottom). (B) EGFR exon 20 sequence electropherograms of IP4 tissue and its derivatives. The electropherograms were analyzed by CRISP-ID and the Mixed Sequence Reader. Both analyses identified the same heterozygous insertion mutation of EGFR exon 20 as indicated in (A) in both cell lines as in the primary tumor.
In an ordinary culture system, the lifespan of primary cells is finite. After a certain number of passages, the primary cells undergo irreversible cell-cycle arrest called senescence. Previous study has shown that HPV16 E6, which activates TERT, and E7 which inhibits pRB, is sufficient to extend the lifespan of cells. However, the ability of E6 to activate TERT varies among high-risk HPVs, and in some cases, E6 and E7 might not be sufficient to immortalize primary epithelial cells. Therefore, the addition of TERT into the combination of E6 and E7 could be sufficient to immortalize the cells. In the current study, the primary HPV58-positive cells, NP3 became senescent at about passage 12. We therefore tried to immortalize them by transduction of TERT into the cells, which increased lifespan of the cells, leading to generation of NP3/T. Transduction of TERT in combination with mutant CDK4 and cyclin D1 is another technique to induce primary cells to become primary immortal cells. The transduction of TERT into primary cells results in restoration of telomeres, while transduction of mutant CDK4 and cyclin D1 inactivates pRB by phosphorylation leading to enhance cell proliferation and cell-cycle progression without compromising differentiation potential. In human-derived corneal epithelial cells, forced expression of mutant CDK4 and cyclin D1 together with TERT could induce immortalization while retaining the

Table 2. Characteristics of the established sinonasal cells.

|                  | NP2      | NP2/K4DT | NP3      | NP3/T    | IP4      | IP4/K4DT |
|------------------|----------|----------|----------|----------|----------|----------|
| Cell morphology  | Polygonal| Polygonal| Polygonal| Polygonal| Polygonal| Polygonal|
| Population doubling time (hr.) | 62       | 59       | 63       | 62       | 55       | 51       |
| HPV infection    | No       | No       | Yes (HPV58) | Yes (HPV58) | No       | No       |

**Figure 6.** Constitutive activation of the EGFR signaling pathway in the IP4 cells harboring the P772_H773insPYNP mutation in EGFR exon 20. The cells were cultured in triplicate 6-well plates, starved overnight in serum- and EGF-free FYAD medium, then incubated in the presence or absence of 50 ng/ml of EGF for 30 min prior to harvesting cell lysates and analyzed by western blotting. The total and the phosphorylated levels of EGFR, AKT, and MAPK were detected by the antibodies described in Methods (left panel), and the intensities of individual bands were indicated by bar graphs (right panels). Note that the phosphorylated levels of EGFR, AKT, and MAPK were increased in both presence and absence of EGF in culture medium in IP4 cells. Asterisks indicate a statistically significant difference (p < 0.05), and "ns" indicates not significant.
Figure 7. Epithelial origin of established primary cells and the mRNA expression level of EGFR, p53, KRAS, and PIK3CA in primary tumor tissues and established cells. (A) Total cell proteins prepared from NP2, NP3, and IP4 cells cultivated in FYAD medium were analyzed for cytokeratin 14 as well as vinculin as a loading control by western blotting. (B,C) Total RNA was extracted from primary tumor tissues (B) and established cells (C) and analyzed for expression of several genes by RT-qPCR as described in Methods. Note that established cells showed a similar expression pattern of target genes to their primary tumors. Asterisks indicate statistically significant difference (*p < 0.05; **p < 0.01; ***p < 0.001), and “ns” indicates not significant.
characteristics of the primary cells. These results indicate that the cell-cycle regulator networks are associated with cell-cycle arrest, especially p16/Rb signaling pathways. In the current study, the primary HPV-negative nasal cells, NP2 and IP4, become senescent at about passage 13. To immortalize them, TERT in combination with mutant CDK4 and cyclin D1 were transduced into the cells, leading to generation of NP2/K4DT and IP4/K4DT.

STR profiles of primary and primary immortal cells were compared to STR profiles of the primary tumor tissues. Results confirmed their individual origin (Table 1). Previously, cellular immortalization using mutant CDK4 and cyclin D1 in combination with TERT (K4DT) could generate immortalized cells with an intact chromosomal condition such as in human dental pulp stem cells, PT-50. However, this system sometimes generated immortalized cells with chromosomal abnormalities. In immortalized cells (using the K4DT system) from the Bonin flying fox (Pteropus pselaphon), monosomy of chromosome 14 was observed in 90% (45/50) of the cell population. In human ovarian surface epithelial cells, chromosomal instability was found in 8% of immortalized cells, HOSE1. Therefore, the chromosomal status of each established cell cultures was investigated to explore the effect on the chromosomal stability of transgenes used for generating primary immortal cells. Karyotypic and G-banding results revealed that all the primary cells examined maintained normal diploid appearance. However, abnormal karyotypes were found in some populations of the primary immortal cells. A part of chromosome number 6 was deleted (46,XY.del(6)(q21qter)) and chromosome number 8 exhibited an addition (46,XY,add(8) (q24)) in 58% and 52% of NP2/K4DT and IP4/K4DT populations, respectively. This result suggests that transduction of mutant CDK4 and cyclin D1 in combination with TERT (K4DT) sometimes induced chromosomal abnormality or enabled such cells to survive. As chromosomal abnormalities are rarely found in nasal cells, it is unlikely that these transgenes themselves induce constitutive chromosomal instability. Though high-risk HPV E6 and E7 oncoproteins are used to independently induce numerical and structural chromosome instability, HPV58-positive primary NP3 cells and 10% NP3/T cells showed normal diploid karyotype, suggesting expression levels of E6 and E7 oncoproteins in these cells were low. However, trisomy chromosome number 4 (47,XY, + 4) was found in 90% of the NP3/T cell populations. Duesberg and McCormack investigated karyotypic flexibility of primary human kidney (HA1 and HA1-2) and skin cells (BJ) after transfection with overexpressed telomerase. Their results suggested that such cells could contain clonal and flexible karyotypes. In addition, an increased aneuploid cell population was observed in cen3tel cell culture at PD100 compared to PD37 (100% vs 60%) after transfection with overexpressed telomerase. In human mammary epithelial cells (HMEC), increase of c-MYC oncogene expression was observed with increasing population doublings (PDs) after transduction with TERT. Moreover, reduction of the cell-cycle regulator protein, p16INK4a, was observed in the late passages of T-HME (TERT immortalized HMEC) compared to pre-senescent HME cells, while the transcriptional activity of E2F1 increased sixfold. On the other hand, functionally normal p53 and its downstream targets were not affected by overexpression of telomerase. This suggests that overexpression of oncogenes such as MYC in TERT-transduced cells might be risk factors for chromosomal instability of the cells.

Tumorigenesis is generally recognized as being associated with the accumulation of genetic alterations; various mutations, such as TP53, ERBB1, NOTCH1, HRAS, KRAS, and PIK3CA are common in human head and neck cancers. Mutations are more frequent in SIP-associated squamous-cell carcinoma (SCC) than in SIP. We examined our cells for common mutations reportedly involved in the pathogenesis of NP and SIP: none contained mutations in TP53, KRAS, or PIK3CA. Mutations in TP53 are frequently found in SIP and SIP-associated SCC and might be involved in malignant transformation. In addition, significantly increased expression of p53 was found in SIP with dysplasia and SIP with SCC compared to normal control, consistent with our result that IP4 tissue, which is SIP with mild dysplasia showed higher p53 level compared to NP tissues and normal control. The similar result was observed in IP4 and IP4/K4DT cells compared to NP cells (Fig. 7C). KRAS mutations in NP are 17% and 35% in exons 11 and 12, respectively. The expression of KRAS is significantly increased in NP compared to adjacent normal tissue and associated with advanced stages of NP. KRAS mutations are

### Table 3. Patients and tumor characteristics.

| NP2 | NP3 | IP4 |
|-----|-----|-----|
| Age (year) | 19 | 11 | 68 |
| Gender | Male | Male | Male |
| Diagnosis | NP | NP | SIP |
| Tumor origin | Maxillary | Maxillary | Nasal cavity (middle turbinate) |
| Staging | Grade III | Grade III | Keouse staging T4 |
| Eosinophil count | Low (9/HPF) | High (50/HPF) | – |
| Dysplastic change | – | – | Mild |
| Recurrence | Yes | No | Yes |
| HPV | No | Yes (HPV 58) | No |
| EGFR mutation | No | No | Yes (P772_H773insPYPNY) |
| Pre-treatment | Intranasal corticosteroid and antihistamine | Intranasal corticosteroid and antihistamine | None |
| Post-treatment | Intranasal corticosteroid and antihistamine | Intranasal corticosteroid and antihistamine | None |

Patients and tumor characteristics.
significantly more common in SIP with dysplasia or SCC (10%) compared to SIP without dysplasia\(^{46}\). In contrast, another finding revealed that KRAS mutations do not occur in cell lines derived from sinonasal squamous-cell carcinoma (SNSCC) tissues\(^{49}\). KRAS mutation was not observed in our IP4 and IP4/K4DT cells, or in the IP4 tissue. However, mRNA expression results revealed increased expression of KRAS in IP4 tissue and their derivatives, IP4 and IP4/K4DT cells, which were established from SIP with mild dysplasia (Fig. 7B,C). According to a previous report, EGFR is involved in many types of human tumors. EGFR mutations are frequently found in SIP (88%), mostly in the form of insertions between A767 and C775 in exon 20\(^{46}\). A mutation in EGFR was observed only in our IP4 and IP4/K4DT cells, as well as in the IP4 primary tissue. This mutation was an insertion mutation in exon 20 called P772_H773insPYNPNP (Table 1). It is similar to a previously reported EGFR mutation in exon 20 that was found in SNSCC4 and UM-SCC-112 cell lines derived from SIP-associated SNSCC\(^{49}\). EGFR mutations located between residues A767 and C775 affect the loop following the C-helix region of the kinase domain, resulting in constitutive activation of EGFR\(^{51}\). We experimentally revealed this EGFR mutation at P772_H773insPYNPNP, which results in ligand-independent activation of EGFR (Fig. 6). The previous study demonstrated that insertions in EGFR exon 20 lead to independent dimerization activation of EGFR and autophosphorylation\(^{52}\), consistent with our finding of increased expression of EGFR and p-EGFR in IP4 cells, and IP4/K4DT cells. IP4 and IP4/K4DT cells in which HPV-DNA was not found by real-time PCR. This is also consistent with a previous report which investigated the relationship between EGFR mutations and HPV infection in SIP and found they are mutually exclusive\(^{53}\), suggesting that HPV infection and EGFR mutation are important, but independent, risk factors for SIP development and progression\(^{54}\). Overexpression of EGFR was found in laryngeal squamous cell carcinoma and its expression level was significantly associated with HPV infection\(^{55}\). The E5 oncoprotein of HPV could enhance EGFR surface expression and activation, inducing cell-cycle progression\(^{56}\). This might explain the higher EGFR expression levels in our NP3 tissue and the newly established HPV58-positive cells, NP3 and NP3/T, than seen in our HPV-negative NP2 tissue and cells derived from it (Fig. 7B,C). In addition, significantly increased of mRNA and protein expression level of EGFR was found in SIP compared to normal control and the expression level was related with dysplastic change of the cell\(^{56}\), consistent with our result that higher expression of EGFR was found in both IP4 tissue and cells derived from it compared to NP tissue and NP cells, respectively (Fig. 7B,C). Our newly established cell cultures appear to exhibit less genetic alteration than do other previously established SIP-associated SNSCC cells\(^{49,57}\).

In conclusion, this study describes new primary NP and IP cell cultures with unique characteristics derived from different clinical tumor specimens. These were successfully immortalized using TERT alone for HPV 58-positive cells, or using a combination of TERT, mutant CDK4, and cyclin D1 in HPV-negative cells. These cell cultures are representative of NP and SIP tissues in both clinical and genetic characteristics. They will be good in vitro models, useful for the study of NP and SIP, as well as for preclinical testing of new therapeutic strategies for NP and SIP.

**Methods**

**Patient histories and tumor characteristics.** Fresh tissue samples were collected from NP and SIP patients who underwent surgical treatment at Srinagarind Hospital, Faculty of Medicine, Khon Kaen University. The written informed consent was obtained from all patients. Tissue samples were collected, and all experiments were performed in accordance with the approved guidelines of the Khon Kaen University Ethics Committee in Human Research. An overview of patient data and characteristics of cell lines are shown in Table 3.

NP2: A 19-year-old male was diagnosed with a recurrent nasal polyp grade III of the maxillary sinus with low mucosal eosinophil count (9/high-power field (HPF)). An intranasal corticosteroid and antihistamine were used before and after surgical treatment.

NP3: A 11-year-old male was diagnosed with a nasal polyp grade III of the maxillary sinus with a high mucosal eosinophil count (50/HPF). HPV58 DNA was detected in the tumor tissue. An intranasal corticosteroid and antihistamine were used before and after surgical treatment.

IP4: A 68-year-old male was diagnosed with a recurrent inverted papilloma of the nasal cavity (middle turbinate) with Krouse staging T4. Histological examination showed mild dysplasia. EGFR mutation in exon 20 was observed in the tumor tissue. No medical treatment was used before or after surgical treatment.

**Cell-line establishment.** Fresh tumor tissue samples from the operating room were cut into several small fragments, that were transferred to a 60 mm cell culture dish, covered with FYAD medium (F culture medium\(^{58}\) supplemented with 10 µM Y-27632 (Selleck, USA), 500 nM A-83-01 (TOCRIS, UK) and 500 nM DMH-1 (Selleck, USA)), and incubated in 5% CO\(_2\) at 37 °C. Five to seven days later, outgrowths of tumor and fibroblast cells were observed. Overgrowth by fibroblasts was prevented by repeated selective trypsinization. Three primary cell cultures were obtained and named NP2, NP3 (from NP tissues), and IP4 (from SIP tissue).

**Cell proliferation.** Each established cell culture was seeded at a density of 70,000 cells per well in three 6-well plates covered with FYAD medium and incubated in 5% CO\(_2\) at 37 °C. Cells in triplicate wells were trypsinized, stained with trypan blue and were counted for viable cells by using a haemacytometer every 24 h for 5 days. The experiment was performed in 3 independent experiments. The population-doubling time (DT) was calculated using the following formula: DT = T/ln2(Xe/Xb), when T is the incubation time in any units, Xb is the cell number at the beginning of the incubation time, and Xe is the cell number at the end of the incubation time.
Given in Table 4. The electropherograms were analyzed by CRISP-ID61 and the Mixed Sequence Reader62. Genetic Analyzer (Applied Biosystems, USA). Both strands were sequenced for confirmation. The primers are

| KRAS in exon 2 and EGFR in exons 19–20 mutations were analyzed by direct sequencing using the 3130xl were purified with GF1-AmbiClean Kit (Vivantis, Malaysia). TP53 in exons 5–9, PIK3CA in exons 9 and 20, were cultivated in FYAD medium until 90% confluence and collected cell lysates using lysis buffer. In an EGF-treatment experiment, the cells were starved overnight in serum- and EGF-free FYAD medium, then incubated in the presence or absence of 50 ng/ml of EGF for 30 min prior to harvesting cell lysates. Protein expression of CDK4, cyclinD1, cytokeratin 14, EGFR, p-EGFR, AKT, p-AKT, MAPK and p-MAPK were investigated by western blotting. The western blot was performed as described previously66. Antibody against CDK4 (BD Biosciences, USA, Cat# 610,147, RRID:AB_397548), cyclinD1 (BD Biosciences, UAS, Cat# 554,180, RRID:AB_395291), EGFR (Cell Signaling Technology, USA, Cat# 2646, RRID:AB_2230881), p-EGFR (Cell Signaling Technology, USA, Cat# 2234, RRID:AB_331701), cytokeratin 14 (Covance, USA, Cat# PRB-155P, RRID:AB_292096), AKT

| PCR and RT-qPCR primers
| Target DNA was amplified using the SYBR-green real-time polymerase chain reaction (real-time PCR).

| Table 4. Sequences of primers used in this study.

| Sequencing primers | F-primer sequence | R-primer sequence | References |
|---------------------|-------------------|-------------------|------------|
| TP53-Exon5-6        | 5'-TCTGTCCTCTCACTTCTTCT-3' | 5'-CAGTGCAACACCACCGTTAAC-3' | 88 |
| TP53-Exon7-9        | 5'-CCTGCTTGGCCACAGTTCT-3' | 5'-GGGCAATTGCAGTTAAC-3' | 88 |
| PIK3CA-Exon9        | 5'-CTGTGAAATCCAGGAGGGGAAA-3' | 5'-ACATGCTGATGGACGCAAAAT-3' | 88 |
| PIK3CA-Exon20       | 5'-ATGATGGTACTCTGCTGGAAT-3' | 5'-GGGTCTTTGCCTGCTGAGAT-3' | 88 |
| KRAS-Exon2          | 5'-TACTGCTGGAGATTATGATGTG-3' | 5'-CTGTATCAGAGAATGTCCTG-3' | 63 |
| EGFR-Exon19         | 5'-TGTCATCGCTGTAACATCC-3' | 5'-TGTTGAGTAGGACGGCTGCT-3' | 64 |
| EGFR-Exon20         | 5'-ATGGCATTCATGGGCTCTCA-3' | 5'-ATCCCCAGGGCAACCTCTG-3' | 64 |

Sequences of primers used in this study.

| Sequencing primers | F-primer sequence | R-primer sequence | References |
|---------------------|-------------------|-------------------|------------|
| GP5+/GP6+           | 5'-TTTAATCTGTTGGAATGATACTAC-3' | 5'-GAAAATAAAACCTGATTTACATATTTCC-3' | 66 |
| p53                 | 5'-TGAAGGCTCCCAAGAAGCCAGC-3' | 5'-CAGAAGAGTCAAGGGGCTG-3' | 66 |
| PIK3CA              | 5'-AATATCTGGAAGAGGGG-3' | 5'-CGGTGAAAGGGTAAATGGTG-3' | 66 |
| KRAS                | 5'-TGTGCTTGAGCAGGATATACG-3' | 5'-GGGTAGGGCAGAGGTGCCTGAC-3' | 66 |
| EGFR                | 5'-CCAGATTTGATCGCAGGAG-3' | 5'-CTTTCCCTCACGAGGACTCCG-3' | 66 |
| GAPDH               | 5'-TCATCAAGCAATGCCCTCCTGCA-3' | 5'-TGTTGAGTGGCAATGCGCA-3' | 66 |

This study

DNA extraction. DNA was extracted using a commercially available system, DNeasy Blood and Tissue kits (QIAGEN, Germany), according to the manufacturer's instructions. The extracted DNA was quantified by GAPDH amplification using SYBR-green real-time polymerase chain reaction (real-time PCR).

HPV DNA detection and genotyping. The presence of HPV DNA in the established cell lines was investigated using GP5+/GP6+ primers65 and SYBR-green real-time PCR. DNA derived from SiHa and HeLa cells was used as positive controls. Samples that were positive according to SYBR-green real-time PCR were further investigated for HPV genotype by reverse line-blot hybridization (RLBH) as previously described60.

Short tandem repeat (STR) analysis. Twenty-three autosomal markers (D3S1358, vW A, D16S539, CSF1PO, D6S1043, D8S1179, D21S11, D18S51, D5S818, D2S441, D12S391, D1S1656, D13S317, D7S820, Penta E, Penta D, TH01, D12S391, D2S1338, and TPXO), a quality indicator system, and amelogenin (AMEL), sex-identification markers were amplified using the commercial VeriFiler Plus PCR Amplification Kit, according to the manufacturer's protocol. The amplicons were genotyped by multi-capillary electrophoresis on an Applied Biosystems 3130xl Genetic Analyzer, and the allele calling was performed by the GeneMapper ID-X Software Version 1.4 (Applied Biosystems).

Gene mutation analysis. Target DNA was amplified by PCR: 1 cycle of 98 °C for 1 min; 30 cycles of 98 °C for 10 s, 55 °C for 30 s, and 68 °C for 90 s, followed by 5 min at 68 °C and kept cold at 12 °C. The PCR products were purified with GF1-AmbiClean Kit (Vivantis, Malaysia). TP53 in exons 5–9, PIK3CA in exons 9 and 20, KRAS in exon 2 and EGFR in exons 19–20 mutations were analyzed by direct sequencing using the 3130xl Genetic Analyzer (Applied Biosystems, USA). Both strands were sequenced for confirmation. The primers are given in Table 4. The electropherograms were analyzed by CRISP-ID66 and the Mixed Sequence Reader62.

Gene expression analysis. RNA was extracted using TRIzol Reagent (Invitrogen, USA), according to the manufacturer's instructions. The extracted RNA was subjected to cDNA synthesis using SuperScript III First-Strand Synthesis System (Invitrogen, USA), according to the manufacturer's instructions. mRNA expression levels of EGFR, p53, KRAS, PIK3CA, and the internal control, GAPDH were investigated by RT-qPCR (Applied Biosystems QuantStudio 6 Flex Real-Time PCR System, Thermo Fisher Scientific, USA) using specific primers shown in Table 4.

Western-blot analysis. To determine the expression level of CDK4, cyclinD1 and cytokeratin 14, cells were cultivated in FYAD medium until 90% confluence and collected cell lysates using lysis buffer. In an EGF-treatment experiment, the cells were starved overnight in serum- and EGF-free FYAD medium, then incubated in the presence or absence of 50 ng/ml of EGF for 30 min prior to harvesting cell lysates. Protein expression of CDK4, cyclinD1, cytokeratin 14, EGFR, p-EGFR, AKT, p-AKT, MAPK and p-MAPK were investigated by western blotting. The western blot was performed as described previously66. Antibody against CDK4 (BD Biosciences, USA, Cat# 610,147, RRID:AB_397548), cyclinD1 (BD Biosciences, UAS, Cat# 554,180, RRID:AB_395291), EGFR (Cell Signaling Technology, USA, Cat# 2646, RRID:AB_2230881), p-EGFR (Cell Signaling Technology, USA, Cat# 2234, RRID:AB_331701), cytokeratin 14 (Covance, USA, Cat# PRB-155P, RRID:AB_292096), AKT

Sci Rep | (2021) 11:17100 | https://doi.org/10.1038/s41598-021-96444-y

natureportfolio
Cell immortalization. Fragments of human mutant CDK4 (CDK4R24C: a p16INK4A-resistant form of CDK4), the encephalomyocarditis virus internal ribosome entry site (IRES) from pIRESG-EGFP (Clontech, USA) and human cyclinD1 were PCR-amplified and recombined with pDONR221P1-P4, pDONR221P4-P3r, and pDONR221P3-P2, respectively by BP recombination according to the manufacturer's instruction (Invitrogen, USA), and then recombined with CSII-CMV-RfA to generate CSII-CMV-CDK4R24C-IRES-Cyclin D1. To immortalize the nasal cells, CSII-CMV-TERT and CSII-CMV-CDK4R24C-IRES-Cyclin D1 recombinant lentiviruses were produced as previously described. Recombinant viral fluid was inoculated onto the early passage of nasal cells in the presence of 4 μg/ml polybrene at the multiplicity of infection of 10. Twenty-four hours post-inoculation, cells were fed with a fresh complete medium. The infected cells were passaged until uninfected control cells had senesced (around passage 10–11).

Statistical analysis. Expression difference between parental and their derivatives, and between treated and untreated in the same cell lines were calculated using t-test in GraphPad Prism 5. Cell proliferation and mRNA expression in tissue samples and in different cell lines were analyzed by one-way ANOVA using STATA. Differences were considered statistically significant at $p < 0.05$. Data are representative of 3 independent experiments and presented as the mean ± SD.

Ethical approval. The study was approved by the Khon Kaen University ethics committee in human research (HE611288).

References

1. Settipane, R. A., Peters, A. T. & Chiu, A. G. Chapter 6: Nasal polyps. Am. J. Rhinol. Allergy 27(1), S20–25. https://doi.org/10.2500/ajra.2013.27.3926 (2013).
2. Georgy, M. S. & Peters, A. T. Chapter 7: Nasal polyps. Allergy Asthma Proc. 33(Suppl 1), 22–23. https://doi.org/10.2500/aap.2012.33.33537 (2012).
3. Bateman, N. D., Fahy, C. & Woolford, T. J. Nasal polyps: Still more questions than answers. J. Laryngol. Otol. 117, 1–9. https://doi.org/10.1012/jlto.2002.0221503321046577 (2006).
4. Ta, N. H. Will we ever cure nasal polyps? Ann. R. Coll. Surg. Engl. 101, 35–39 (2019).
5. Kirtreesaksul, V. Nasal polyps: The relationship to allergy, sinonasal infection and histopathological type. J. Med. Assoc. Thailand = Chotmaihet thangphaet 87, 277–282 (2004).
6. Bucholtz, G. A. et al. PCR analysis of nasal polyps, chronic sinusitis, and hypertrophied turbinates for DNA encoding bacterial 16S rRNA. Am. J. Rhinol. 16, 169–173 (2002).
7. Telmesani, L. M. Prevalence of allergic fungal sinusitis among patients with nasal polyps. Ann. Saudi Med. 29, 212–214 (2009).
8. Kirtreesaksul, V. Update on nasal polyps: Etiopathogenesis. J. Med. Assoc. Thailand = Chotmaihet thangphaet 88, 1966–1972 (2005).
9. Liao, R. et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy 73, 1459–1469 (2018).
10. Bassiouni, A. et al. The global transcriptomic signature in sinonasal tissues reveals roles for tissue type and chronic rhinosinusitis disease phenotype. Rhinology 58, 273–283 (2020).
11. Yao, Y., Yang, C., Yi, X., Xie, S. & Sun, H. Comparative analysis of inflammatory signature profiles in eosinophilic and noneosinophilic chronic rhinosinusitis with nasal polyps. Biosci. Rep. 40, BS20193101. https://doi.org/10.1042/BSR20193101 (2020).
12. Kim, Y. S. et al. In-depth, proteomic analysis of nasal secretions from patients with chronic rhinosinusitis and nasal polyps. Allergy Asthma Immunol. Res. 11, 691–708 (2019).
13. Wood, J. W. & Cassano, R. R. Inverted papillomas and benign nonneoplastic lesions of the nasal cavity. Am. J. Rhinol. Allergy 26, 157–163 (2012).
14. Eggers, G., Muhling, I. & Hassfeld, S. Inverted papilloma of paranasal sinuses. J. Cranio-maxillofac. Surg. 35, 21–29 (2007).
15. Anari, S. & Carrie, S. Sinonasal inverted papilloma: Narrative review. J. Laryngol. Otol. 124, 705–715 (2010).
16. Thapa, N. Diagnosis and treatment of sinonasal inverted papilloma. Nepalese J. ENT Head Neck Surg. 1, 30–33 (2010).
17. Sham, C. L. et al. Prevalence of human papillomavirus, Epstein–Barr virus, p21 and p53 expression in sinonasal inverted papilloma, nasal polyp, and hypertrophied turbinates in Hong Kong patients. Head Neck 34, 520–533. https://doi.org/10.1002/hed.21772 (2012).
18. Yasumatsu, R. et al. Clinical management of squamous cell carcinoma associated with sinonasal inverted papilloma. Auris Nasus Larynx 44, 98–103 (2017).
19. Yang, Z. et al. Putative biomarkers of malignant transformation of sinonasal inverted papilloma into squamous cell carcinoma. J. Int. Med. Res. 47, 2371–2380 (2019).
20. Tsu, Y. A. et al. Evaluation of correlation of cell cycle proteins and Ki-67 interaction in paranasal sinus inverted papilloma prognosis and squamous cell carcinoma transformation. Biomed. Res. Int. 2014, 634945. https://doi.org/10.1155/2014/634945 (2014).
21. Lisan, Q., Laccourreye, O. & Bonfils, P. Sinonasal inverted papilloma: From diagnosis to treatment. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 133, 337–341. https://doi.org/10.1016/j.anorl.2016.03.006 (2016).
22. Coutinho, G. et al. Surgical outcomes of sinonasal inverted papilloma: A 17 year review. Braz. J. Otorhinolaryngol. https://doi.org/10.1016/j.bjorl.2018.12.011 (2019).
23. Mirabelli, P., Coppola, L. & Salvatore, M. Cancer cell lines are useful model systems for medical research. Cancers https://doi.org/10.3390/cancers11081098 (2019).

Received: 6 January 2021; Accepted: 10 August 2021
Published online: 24 August 2021
24. Kiyono, T. et al. Both Rh/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396, 84–88. https://doi.org/10.1038/39684 (1998).
25. McSharry, B. P., Jones, C. L., Skinner, J. W., Kipling, D. & Wilkinson, G. W. G. Human telomerase reverse transcriptase-immortalized MRC-5 and HCA2 human fibroblasts are fully permissive for human cytomegalovirus. J. Gen. Virol. 82, 855–863. https://doi.org/10.1099/0022-1317-82-4-855 (2001).
26. Guichard, C. et al. Epithelial cell proliferation, apoptosis, and apoptosis inhibition in inverted papillomas. Laryngoscope 108, 116–120. https://doi.org/10.1097/00005537-199805000-00017 (1998).
27. Mumbuc, S. et al. Immunohistochemical analysis of PCNA, Ki67 and p53 in nasal polyposis and sinonasal inverted papillomas. J. Int. Med. Res. 35, 237–241 (2007).
28. Lavezzi, A., Mantovani, M., Cazzullo, A., Turconi, P. & Matturri, L. p53 over-expression and its correlation with PCNA index in nasal polyps. Rhinology 37, 160–163 (1999).
29. Robinson, S., Tan, L. W., James, C., Karakousis, A. & Wormald, P. J. Do nasal polyps and inverted papilloma have similar disorders in cell cycle regulation?. Am. J. Rhinol. 20, 637–640 (2006).
30. Robinson, S., Tan, L. W., James, C., Karakousis, A. & Wormald, P. J. Do nasal polyps and inverted papilloma have similar disorders in cell cycle regulation?. Am. J. Rhinol. 20, 637–640 (2006).
31. Gillison, M. L. Human papillomavirus infection in sinonasal papillomas: systematic review and meta-analysis. Laryngoscope 123, 181–192. https://doi.org/10.1002/lary.23688 (2013).
32. van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446. https://doi.org/10.1038/nature13193 (2014).
33. Fu, B., Quintero, J. & Baker, C. C. Keratinocyte growth conditions modulate telomerase expression, senescence, and immortalization by human papillomavirus type 16 E6 and E7 oncogenes. Can. Res. 65, 7815–7824 (2003).
34. Syrjanen, K. & Syrjanen, S. Detection of human papillomavirus in sinonasal papillomas: systematic review and meta-analysis. Laryngoscope 123, 181–192. https://doi.org/10.1002/lary.23688 (2013).
35. Robinson, S., Tan, L. W., James, C., Karakousis, A. & Wormald, P. J. Do nasal polyps and inverted papilloma have similar disorders in cell cycle regulation?. Am. J. Rhinol. 20, 637–640 (2006).
36. Robinson, S., Tan, L. W., James, C., Karakousis, A. & Wormald, P. J. Do nasal polyps and inverted papilloma have similar disorders in cell cycle regulation?. Am. J. Rhinol. 20, 637–640 (2006).
37. Pei, F. et al. Prevalence and anatomical sites of human papillomavirus, Epstein-Barr virus and herpes simplex virus infections in men who have sex with men, Khon Kaen, Thailand. BMC Infect. Dis. 16, 509. https://doi.org/10.1186/s12879-018-4308-0 (2018).
38. Kiyono, T. et al. Both Rh/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396, 84–88. https://doi.org/10.1038/39684 (1998).
39. Lawrence, M. S. et al. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis 30, 423–431. https://doi.org/10.1093/carcin/bgp067 (2009).
40. Duesberg, P. & McCormack, A. Immortality of cancers: a consequence of inherent karyotypic variations and selections for autonomous, cell-cell cooperation. Cell Cycle 12, 783–802. https://doi.org/10.4161/cc.12730 (2013).
41. Wang, J., Hannon, G. J. & Beach, D. H. Risky immortalization by telomerase. Cell 12, 755–756. https://doi.org/10.1083/25015754.674 (2000).
42. Kim, H. E. et al. Events in the immortalizing process of primary human mammary epithelial cells by the catalytic subunit of human telomerase. Biochem. J. 365, 765–772. https://doi.org/10.1042/BJ20011884 (2002).
43. Lawrence, M. S. et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576–582. https://doi.org/10.1038/nature14129 (2015).
44. Yasukawa, S. et al. Genetic mutation analysis of the malignant transformation of sinonasal inverted papilloma by targeted amplicon sequencing. Int. J. Clin. Oncol. 23, 835–843. https://doi.org/10.1007/s10147-018-1296-1 (2018).
45. Katori, H., Nozawa, A. & Tsukuda, M. Relationship between p21 and p53 expression, human papilloma virus infection and malignant transformation in sinonasal-involved papillomas. Clin. Oncol. (R. Coll. Radiol.) 18, 300–305 (2006).
46. Zaravinmos, Á., Bizakis, J., Soufla, G., Sourvinos, G. & Spandidos, D. A. Mutations and differential expression of the ras family genes in human nasal polyps. Int J Oncol 31, 1051–1059 (2007).
47. García-Inclán, C. et al. Establishment and genetic characterization of six unique tumor cell lines as preclinical models for sinonasal squamous cell carcinoma. Sci. Rep. 4, 4925 (2014).
48. Li, H., Hu, L., Zhang, H. & Wang, D. ERBB1 and ERBB2 overexpression in patients with sinonasal inverted papilloma and inverted papilloma with squamous cell carcinoma in China. Acta Otolaryngol. 139, 1104–1111. https://doi.org/10.1080/000285375.1991.1085200 (1999).
49. Watson, C. W. et al. Human papillomavirus type 18 E5 oncogene supports cell cycle progression and impairs epithelial differentiation by modulating growth factor receptor signalling during the virus life cycle. Oncotarget 8(61), 103581–103600. https://doi.org/10.18632/oncotarget.21658 (2017).
50. Li, H., Hu, L., Zhang, H. & Wang, D. ERBB1 and ERBB2 overexpression in patients with sinonasal inverted papilloma and inverted papilloma with squamous cell carcinoma in China. Acta Otolaryngol. 139, 1104–1111. https://doi.org/10.1080/000285375.1991.1085200 (1999).
51. Swenson, W., Miller, K. A., Wiertz, B., Junghauer, W. N. Jr. & Ondrey, F. G. Establishment and characterization of an inverted papilloma-associated sinonasal squamous cell carcinoma cell line. Int. Forum Allergy Rhinol. 11, 938–940. https://doi.org/10.1002/ 2122739 (2021).
52. Rheinwald, J. G. & Green, H. Serial cultivation of strains of human epidermal keratinocytes: The formation of keratinizing colonies from single cells. Cell 6, 331–343. https://doi.org/10.1016/0021-9954(75)8001-8 (1975).
53. Zehe, B., Wilander, E., Delius, H. & Tommasino, M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Can. Res. 58, 829–833 (1998).
54. Cho, G. et al. Establishment and genetic characterization of six unique tumor cell lines as preclinical models for sinonasal squamous cell carcinoma. Sci. Rep. 4, 4925 (2014).
55. Dehairs, J., Talebi, A., Cheriff, Y. & Swinnen, J. V. CRISP-ID: Decoding CRISPR mediated indels by Sanger sequencing. Sci. Rep. 6, 28973. https://doi.org/10.1038/srep28973 (2016).
62. Chang, C. T. et al. Mixed sequence reader: A program for analyzing DNA sequences with heterozygous base calling. Sci. World J. 2012, 365104. https://doi.org/10.1100/2012/365104 (2012).
63. Kringen, P. et al. Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas. Biotechniques 39, 755–761. https://doi.org/10.2144/00011200 (2005).
64. Munari, F. F. et al. PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaeosophagus and are associated with a worse patient outcome. Infect. Agents Cancer 13, 43. https://doi.org/10.1186/s13027-018-0216-3 (2018).
65. Zhang, W. et al. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J. Thoracic Oncol. 1, 635–647 (2006).
66. Haga, K. et al. Efficient immortalization of primary human cells by p16INK4a-specific short hairpin RNA or Bmi-1, combined with introduction of hTERT. Cancer Sci. 98, 147–154. https://doi.org/10.1111/j.1349-7006.2006.00373.x (2007).

Acknowledgements
This work was supported in part by Japan Agency for Medical Research (Grant number 20jk0210009) to T.K, the Thailand Research Fund and Khon Kaen University through the Royal Golden Jubilee Ph.D. Program (Grant number PHD/0081/2558) to T.N., Khon Kaen University (Grant number B05F630053) to T.E., and Research and Graduate Studies, Khon Kaen University (RP64-4/004) to C.P. We would like to acknowledge Prof. David Blair for the English editing of the MS via Publication Clinic KKU.

Author contributions
C.P., T.E., T.K., and T.N. conceived and designed the experiments. P.K., W.T., and P.V. operated on the patients and provided the tissue material. S.C. provided the clinical and histological data. T.N. initiated and maintained the cell cultures. T.N. performed the proliferation experiments. T.N. and T.K. performed western-blot analysis, gene-mutation analysis, and immortalization. C.P. and T.E. performed the HPV analysis. T.N., C.P., and T.E. performed gene expression analysis. K.M. and T.N. performed STR analysis. T.N., C.P., T.E., and T.K. performed karyotyping. T.N., C.P., T.E., and T.K. wrote the main manuscript text and prepared the figures. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-96444-y.

Correspondence and requests for materials should be addressed to T.K. or C.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021